Monthly Archives: October 2010

Brazil Profile: Latin America's Giant Repositions for Pharma Growth

Brazil claims a bright future as a drug research and clinical trials site — but IP issues continue to raise concerns among the multinational investor community. Health and regulatory officials of Brazil are making the rounds with a message for pharmaceutical companies and clinical research sponsors about what a great place it is to do […]
Posted in Emerging Markets, FDA, Global, Legal, Manufacturing, R&D, Regulatory, Strategy, Supply Chain | Leave a comment

Cancer Testing Times: One Thing the UK Will Not Be Cutting

Buried among the savage, £83 billion-worth of cuts announced by the UK coalition government’s controversial Comprehensive Spending Review last week was confirmation that the Department of Health would not be taking forward the previous government’s pledge to introduce a one-week target for cancer testing. Under the Labour government, the time that it took for a […]
Posted in Europe, Global, Guest Blog | Tagged , , , , | Leave a comment

Pharma Gets the ProPublica Treatment

Alternative news organization and media allies investigate the industry’s payments to doctors—launching a fresh assault on the ethical status quo. By Walter Armstrong Last week, Big Pharma’s practice of paying doctors to do medical education, promote its products, or both was the focus of a multimedia blitz launched by ProPublica in collaboration with National Public […]
Posted in FDA, Legal, Medical Education, Meetings | Tagged , , , , , | 6 Comments

Understanding Serious Adverse Events Takes Serious Cooperation

What if the technology is at hand to prevent adverse reactions to medicines before they start? The International Serious Adverse Events Consortium (iSAEC) came together in 2007 to research the cause of certain drug-induced serious adverse reactions, posing the question, “What if the identification of risk for adverse events were not a random development, but […]
Posted in Agency Insight, FDA, News, R&D | Tagged , | Leave a comment

Industry, Patents and Public Health: Wimps on the Barbie?

The welcome news of a compact between industry and the WHO to fight neglected diseases in the developing world only highlights a much more spotty industry record of engagement on sensitive policy issues like intellectual property rights. One of the industry’s more ambitious policy-driven efforts occurred some five years ago with a strong, well-funded and […]
Posted in Corporate Responsibility, Global, Legal, R&D, Strategy | Tagged , , , , | 1 Comment
  • Categories

  • Meta